GHK-Cu Dosage Guide

GHK-Cu is a tripeptide-copper complex naturally present in human plasma, saliva, and urine. Plasma levels of GHK-Cu decline significantly with age — from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. This age-related decline correlates with diminished regenerative capacity.

Research by Dr. Loren Pickart and others has demonstrated that GHK-Cu stimulates collagen synthesis, promotes angiogenesis, attracts immune cells to sites of injury, and possesses anti-inflammatory and antioxidant properties. Gene expression studies show that GHK-Cu modulates the activity of over 4,000 human genes, generally resetting gene expression toward a healthier, more youthful pattern.

GHK-Cu is administered via multiple routes depending on the research objective:

Topical GHK-Cu is the most widely studied route for skin-related applications. Injectable protocols are used in research targeting systemic anti-inflammatory and regenerative effects.

Topical: Apply once or twice daily to clean, dry skin. Morning and evening applications are standard. GHK-Cu penetrates the skin readily and does not require special delivery systems, though liposomal formulations may enhance absorption.

Injectable: Administer once daily, typically in the morning. No specific fasting requirements. For targeted applications (e.g., hair restoration), some protocols use localized mesotherapy injections 2–3 times weekly.

Cycling: Topical use does not require cycling. Injectable protocols typically run 8–12 weeks on, 4 weeks off. Some research protocols use continuous low-dose administration.

For injectable GHK-Cu:

• Step 1: Swab vial stoppers with alcohol.
• Step 2: For a 50 mg vial, add 5 mL BAC water to yield 10 mg/mL (1 mg per 0.1 mL).
• Step 3: Direct the stream along the glass wall.
• Step 4: Gently swirl. GHK-Cu solution will have a characteristic blue-green tint from the copper.
• Step 5: Store at 2–8°C. Use within 28 days.

Administer subcutaneously with a 29–31 gauge insulin syringe. For localized effects, inject near the target area. GHK-Cu may also be added to topical formulations for transdermal delivery.

• Topical (1–2%): Very well-tolerated. Rare contact sensitivity in subjects with copper allergy. No systemic absorption concerns at topical doses.
• Injectable 200–500 mcg: Mild injection site irritation, temporary blue-green discoloration at injection site (copper pigment). Generally well-tolerated.
• Injectable 500–1000 mcg: Increased likelihood of injection site reactions. Theoretical risk of copper accumulation with prolonged high-dose use, though GHK-Cu copper content is minimal.

Injectable GHK-Cu is for research purposes only and is not FDA-approved for therapeutic use. Topical GHK-Cu is available as a cosmetic ingredient.

Avoid in subjects with Wilson's disease or other copper metabolism disorders. Individuals with copper allergies should not use GHK-Cu in any form. Consult a healthcare provider before initiating injectable protocols.